JP2022537049A5 - - Google Patents

Info

Publication number
JP2022537049A5
JP2022537049A5 JP2021575993A JP2021575993A JP2022537049A5 JP 2022537049 A5 JP2022537049 A5 JP 2022537049A5 JP 2021575993 A JP2021575993 A JP 2021575993A JP 2021575993 A JP2021575993 A JP 2021575993A JP 2022537049 A5 JP2022537049 A5 JP 2022537049A5
Authority
JP
Japan
Prior art keywords
formula
compound
approximately
pharmaceutical material
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038622 external-priority patent/WO2020257571A1/en
Publication of JP2022537049A publication Critical patent/JP2022537049A/ja
Publication of JP2022537049A5 publication Critical patent/JP2022537049A5/ja
Priority to JP2024211105A priority Critical patent/JP2025032197A/ja
Priority to JP2026043961A priority patent/JP2026102795A/ja
Pending legal-status Critical Current

Links

JP2021575993A 2019-06-21 2020-06-19 ベンペド酸の製造方法及びその組成物 Pending JP2022537049A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024211105A JP2025032197A (ja) 2019-06-21 2024-12-04 ベンペド酸を含む製薬材料、医薬製剤及び医薬組成物
JP2026043961A JP2026102795A (ja) 2019-06-21 2026-03-18 ベンペド酸の製造方法及びその組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864873P 2019-06-21 2019-06-21
US62/864,873 2019-06-21
PCT/US2020/038622 WO2020257571A1 (en) 2019-06-21 2020-06-19 Methods of making bempedoic acid and compositions of the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024211105A Division JP2025032197A (ja) 2019-06-21 2024-12-04 ベンペド酸を含む製薬材料、医薬製剤及び医薬組成物

Publications (2)

Publication Number Publication Date
JP2022537049A JP2022537049A (ja) 2022-08-23
JP2022537049A5 true JP2022537049A5 (cg-RX-API-DMAC7.html) 2023-06-16

Family

ID=71528020

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021575993A Pending JP2022537049A (ja) 2019-06-21 2020-06-19 ベンペド酸の製造方法及びその組成物
JP2021575994A Withdrawn JP2022536979A (ja) 2019-06-21 2020-06-19 塩形態のベンペド酸及びそれを使用する方法
JP2024211105A Pending JP2025032197A (ja) 2019-06-21 2024-12-04 ベンペド酸を含む製薬材料、医薬製剤及び医薬組成物
JP2026043961A Pending JP2026102795A (ja) 2019-06-21 2026-03-18 ベンペド酸の製造方法及びその組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021575994A Withdrawn JP2022536979A (ja) 2019-06-21 2020-06-19 塩形態のベンペド酸及びそれを使用する方法
JP2024211105A Pending JP2025032197A (ja) 2019-06-21 2024-12-04 ベンペド酸を含む製薬材料、医薬製剤及び医薬組成物
JP2026043961A Pending JP2026102795A (ja) 2019-06-21 2026-03-18 ベンペド酸の製造方法及びその組成物

Country Status (13)

Country Link
US (11) US12344578B2 (cg-RX-API-DMAC7.html)
EP (3) EP3986860A1 (cg-RX-API-DMAC7.html)
JP (4) JP2022537049A (cg-RX-API-DMAC7.html)
KR (3) KR20220024815A (cg-RX-API-DMAC7.html)
CN (3) CN112437765A (cg-RX-API-DMAC7.html)
AU (3) AU2020296094B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025964A2 (cg-RX-API-DMAC7.html)
CA (2) CA3243601A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032779T3 (cg-RX-API-DMAC7.html)
HU (1) HUE072061T2 (cg-RX-API-DMAC7.html)
IL (3) IL288909A (cg-RX-API-DMAC7.html)
MX (2) MX2021015936A (cg-RX-API-DMAC7.html)
WO (2) WO2020257573A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112437765A (zh) 2019-06-21 2021-03-02 艾斯柏伦治疗公司 贝派地酸的盐形式及其使用方法
US12528759B2 (en) 2019-10-03 2026-01-20 Synthon B.V. Crystalline forms of bempedoic acid
EP4069668A1 (en) 2019-12-06 2022-10-12 Synthon B.V. Crystalline forms of sodium salt of bempedoic acid
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法
WO2021255180A1 (en) * 2020-06-19 2021-12-23 Synthon B.V. Salts of bempedoic acid
CN112521282A (zh) * 2020-12-02 2021-03-19 苏州汉德创宏生化科技有限公司 一种贝派地酸中间体及其合成方法
WO2022149161A1 (en) * 2021-01-05 2022-07-14 Dr. Reddy's Laboratories Limited Process for preparation of bempedoic acid and its intermediates
JP2024521354A (ja) 2021-06-02 2024-05-31 エスペリオン・セラピューティクス・インコーポレイテッド ベンペド酸とトルバブタンを含む組成物及びそれらを用いた治療方法
CN115504914B (zh) * 2021-06-23 2024-05-07 武汉武药科技有限公司 一种贝派地酸中间体的制备方法
CN114436837B (zh) * 2021-12-27 2024-02-20 甘李药业股份有限公司 一种贝派地酸中间体的纯化方法
WO2023187833A1 (en) * 2022-03-30 2023-10-05 Enaltec Labs Private Limited A novel salt of bempedoic acid
CN117551009A (zh) * 2022-08-05 2024-02-13 武汉武药科技有限公司 一种贝派地酸中间体的合成方法
WO2024151311A1 (en) 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid
CN116589341A (zh) * 2023-04-14 2023-08-15 苏州汉德创宏生化科技有限公司 一种抗高血酯药物中间体的制备方法
TW202602886A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Pcsk9抑制劑及其使用方法
TW202539678A (zh) 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Pcsk9抑制劑及其使用方法
TW202602866A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Pcsk9抑制劑及其使用方法
TW202612699A (zh) 2024-05-16 2026-04-01 瑞典商阿斯特捷利康公司 組合療法
WO2026125708A1 (en) 2024-12-12 2026-06-18 Krka, D.D., Novo Mesto Tablets comprising bempedoic acid or bempedoic acid and ezetimibe

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
US3441605A (en) 1965-02-17 1969-04-29 Wallace & Tiernan Inc Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
GB1196595A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Lactone
GB1196597A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of an Oxido-Cyclodecene
GB1196598A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Ketosebacic Acid
FR1545224A (fr) 1966-12-21 1968-11-08 Geigy Ag J R Procédé de préparation de l'acide sébacique
GB1196596A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a hydroxysebacic acid
GB1196594A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Improvements in and relating to the production of Sebacic Acid
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4281200A (en) 1979-08-30 1981-07-28 The Dow Chemical Company Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
JPS5639033A (en) 1979-09-04 1981-04-14 Kao Corp Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (it) 1983-05-30 1987-04-08 Luso Farmaco Inst 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione
JPS59232811A (ja) 1983-06-16 1984-12-27 Sumitomo Chem Co Ltd 芳香族ポリアミドイミド樹脂成形体の製造方法
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4896344A (en) 1984-10-15 1990-01-23 Grady John K X-ray video system
US4634119A (en) 1985-07-11 1987-01-06 Pesthy Paul K Resilient exercise machine with body support platform
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Dnaおよびその用途
US5254589A (en) 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5420339A (en) 1993-11-22 1995-05-30 Warner-Lambert Company Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
JP2937012B2 (ja) 1994-04-08 1999-08-23 時久 増田 角筒包装袋の製造方法及び装置
US5504073A (en) 1994-07-01 1996-04-02 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5578639A (en) 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CZ127198A3 (cs) 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
JP4139448B2 (ja) 1996-08-13 2008-08-27 信越化学工業株式会社 α−ブロモ,ω−クロロアルカンの製造方法
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6093744A (en) 1997-04-21 2000-07-25 Warner-Lambert Company N-acyl sulfamic acid esters useful as hypocholesterolemic agents
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
EP1047421A2 (en) 1997-11-25 2000-11-02 Warner-Lambert Company Inhibition of lipoprotein oxidation
US6459003B1 (en) 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
CN1962596A (zh) 2000-10-11 2007-05-16 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
WO2002030884A2 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス,インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7053046B2 (en) 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US7335689B2 (en) 2003-01-23 2008-02-26 Esperion Therapeutics, Inc. Dihydroxyl compounds and compositions for cholesterol management and related uses
US7705177B2 (en) 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
JP4553181B2 (ja) 2004-03-25 2010-09-29 株式会社サタケ 残留農薬分析方法
US8209479B2 (en) 2007-07-18 2012-06-26 Google Inc. Memory circuit system and method
JP6295205B2 (ja) 2012-01-06 2018-03-14 ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. 心血管疾患のリスクを低減する方法
US9662307B2 (en) * 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2014160729A1 (en) 2013-03-28 2014-10-02 Cellworks Research India Pvt. Ltd Composition and method for treating cancer
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
MX392182B (es) 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
MX2019009418A (es) 2017-02-08 2019-10-02 Esperion Therapeutics Inc Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.
WO2018209257A1 (en) 2017-05-11 2018-11-15 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
CN107628975B (zh) 2017-09-17 2019-10-29 贵州医科大学 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用
CN109721486A (zh) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 一种8-羟基-2,2,14,14-四甲基-十五烷二酸的合成方法
EP3752133A1 (en) 2018-02-16 2020-12-23 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
EP3666750A1 (en) * 2018-12-10 2020-06-17 Sandoz AG Crystalline form of bempedoic acid
JP2022516530A (ja) * 2018-12-31 2022-02-28 ルピン・リミテッド ベンペド酸の新規塩及び多形体
CN112437765A (zh) 2019-06-21 2021-03-02 艾斯柏伦治疗公司 贝派地酸的盐形式及其使用方法
EP4069668A1 (en) * 2019-12-06 2022-10-12 Synthon B.V. Crystalline forms of sodium salt of bempedoic acid
WO2022149161A1 (en) 2021-01-05 2022-07-14 Dr. Reddy's Laboratories Limited Process for preparation of bempedoic acid and its intermediates

Similar Documents

Publication Publication Date Title
CN101573368B (zh) 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物
CN102549005B (zh) 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-[4-((S)-四氢呋喃-3-基氧基)-苄基]-苯的晶型的制备方法
JP2023511105A5 (cg-RX-API-DMAC7.html)
TW201406728A (zh) 具有ep1受體活性之經取代的三環化合物(二)
EA034409B1 (ru) Способы получения кристаллического фенилацетата l-орнитина
CA3001850A1 (en) Solabegron zwitterion and uses thereof
WO2023241507A1 (zh) 一种炔基吡啶类化合物的晶型及其制备方法
CN104159584A (zh) 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
TWI464162B (zh) 新穎溶劑合物結晶
US20120309990A1 (en) Processes for the Purification of Lubiprostone
US20130096325A1 (en) Polymorphic forms of lubiprostone
EP2524920A1 (en) Novel Crystalline Asenapine Hydrochloride Salt Forms
CA2794389A1 (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
CA2738543A1 (fr) Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
TWI917379B (zh) (R)-羥布托尼(Oxybutynin)鹽酸鹽之多晶形式
JP5550696B2 (ja) 置換フェニルアルカン酸エステルの新規結晶及び製造方法
JP2008526836A (ja) シブトラミンの無機酸塩
JP2019500385A (ja) モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途
US20240239791A1 (en) Processes for the synthesis of valbenazine
WO2008007691A1 (en) Salt of morpholine compound
KR102709537B1 (ko) 초순수 트레프로스티닐의 효율적인 결정화 방법 및 그로부터 제조된 결정
WO2013149996A1 (en) Substituted tricyclic compounds with activity towards ep1 receptors
JP5613780B2 (ja) ラミブジンシュウ酸塩及びその製造方法
TH2101007976A (th) วิธีการผลิตกรดเบมพีโดอิกและองค์ประกอบของสิ่งเดียวกัน
JP7776442B2 (ja) (r)-オキシブチニン塩酸塩の多形形態